Description: Aytu BioScience, Inc. is a commercial-stage healthcare company focused on acquiring, developing and commercializing products in the field of urology. The Company focuses on hypogonadism, prostate cancer, urinary tract infections and male infertility. The Company markets ProstaScint (capromab pendetide), a radio imaging agent indicated to detect the prostate specific membrane antigen (PSMA) in the assessment and staging of prostate cancer. The Company's pipeline includes MiOXSYS, an in vitro diagnostic device. MiOXSYS system is a point-of-care semen analysis system, used for diagnosis and management of male infertility. The Company holds the United States rights to Natesto (testosterone), a formulation of testosterone delivered through a nasal gel. Natesto is used for the treatment of hypogonadism (low testosterone) in men. The Company, through its wholly-owned subsidiary Nuelle, Inc., is focused on women’s sexual wellbeing and intimacy.
Home Page: aytubio.com
AYTU Technical Analysis
373 Inverness Parkway
Englewood,
CO
80112
United States
Phone:
720 437 6580
Officers
| Name | Title |
|---|---|
| Mr. Joshua R. Disbrow | Chairman & CEO |
| Mr. Mark K. Oki CPA | CFO, Sec. & Treasurer |
| Mr. Christopher Brooke | Chief Operating Officer |
| Mr. Jarrett T. Disbrow Ph.D. | Chief Bus. Officer & Pres of Consumer Health |
| Mr. Greg Pyszczymuka | Chief Commercial Officer |
| Mr. Russ McMahen | Sr. VP of R&D |
| Mr. Ryan J. Selhorn CPA | Exec. VP of Fin. & Bus. Optimization |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 10.6952 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.2432 |
| Price-to-Sales TTM: | 0.1298 |
| IPO Date: | 2017-02-01 |
| Fiscal Year End: | June |
| Full Time Employees: | 164 |